Search Result
Results for "
Cardiomyocytes
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-12273
-
|
|
TGF-β Receptor
Organoid
Microtubule/Tubulin
|
Cardiovascular Disease
Neurological Disease
|
|
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
|
-
-
- HY-13273
-
|
MK-2866; GTX-024; Enobosarm
|
Androgen Receptor
|
Others
Cancer
|
|
Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism .
|
-
-
- HY-W015061
-
-
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
-
- HY-101016
-
17-ODYA
1 Publications Verification
|
Cytochrome P450
Apoptosis
|
Cardiovascular Disease
|
|
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-119695
-
|
Tenivastatin
|
HMG-CoA Reductase (HMGCR)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
Simvastatin acid (Tenivastatin), a hydrolysate of Simvastatin (HY-17502), is a HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-12343
-
ML277
1 Publications Verification
CID-53347902
|
Potassium Channel
|
Cardiovascular Disease
|
|
ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .
|
-
-
- HY-125016
-
TT-10
2 Publications Verification
TAZ-K
|
YAP
|
Cardiovascular Disease
Cancer
|
|
TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity. TT-10 can be used for the research of heart diseases accompanied by cardiomyocyte loss .
|
-
-
- HY-116152
-
|
Ciprofol; HSK3486
|
GABA Receptor
Sirtuin
Keap1-Nrf2
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABAA receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis .
|
-
-
- HY-115292
-
|
Tenivastatin sodium; Simvastatin Impurity A sodium
|
HMG-CoA Reductase (HMGCR)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Simvastatin hydroxy acid (Tenivastatin) sodium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin hydroxy acid sodium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin hydroxy acid sodium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-13815
-
KY02111
5 Publications Verification
|
Wnt
|
Cardiovascular Disease
|
|
KY02111 is a canonical WNT signaling (β-catenin) inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .
|
-
-
- HY-119850
-
|
ARM036; S44121
|
Calcium Channel
|
Cardiovascular Disease
|
|
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .
|
-
-
- HY-N0252
-
|
(+)-3,4-Didehydrocoronaridine
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca 2+ channel (VOCC). Catharanthine has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity .
|
-
-
- HY-118590
-
|
|
Topoisomerase
DNA/RNA Synthesis
Apoptosis
Fungal
|
Infection
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
ICRF-193 is a DNA Topoisomerase II inhibitor. (S,S)- and (R,R)-isomers ICRF-193 make up an racemic mixture, ICRF-196 (HY-118590A). ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia .
|
-
-
- HY-B1467
-
|
|
Potassium Channel
Bacterial
Parasite
Phosphatase
|
Infection
Inflammation/Immunology
|
|
Domiphen bromide is a cationic active quaternary ammonium salt and also an inhibitor of HERG channels (IC50: 9 nM), aminopeptidase-like enzymes, Escherichia coli alkaline phosphatase, and α-chymotrypsin. Domiphen bromide has multiple activities such as antibacterial, antimalarial, and disinfectant properties, and it is also a synergist of Colistin (HY-113678). Domiphen bromide can be used as a chemical preservative and a cationic surfactant, and it can also be used in the research of bacterial infectious diseases such as pharyngitis, thrush, and oral ulcers .
|
-
-
- HY-100744
-
AS8351
1 Publications Verification
NSC51355
|
Histone Demethylase
|
Cardiovascular Disease
|
|
AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells .
|
-
-
- HY-119695A
-
-
-
- HY-174374
-
|
|
Topoisomerase
|
Cardiovascular Disease
|
|
Topobexin is a TOP2B-selective inhibitor with IC50 values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity .
|
-
-
- HY-153999A
-
|
BT200 sodium
|
Integrin
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Rondaptivon pegol (BT200) sodium is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol sodium effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol sodium inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol sodium can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
|
-
-
- HY-164254
-
|
(E/Z)-GA-002
|
Large Tumor Suppressor (LATS)
YAP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Cardiomyocyte proliferation promoting agent-1 ((E/Z)-GA-002), which is an E/Z mixture, is a cardiomyocyte proliferation promoter. GA-002 (single E configuration) is a kinase inhibitor for LATS1 and LATS2, with its IC50 values being 3.93 nM and 3.87 nM respectively. GA-002 can induce the expression of genes regulated by the Hippo pathway, inhibit the phosphorylation of YAP/TAZ, and induce the nuclear translocation of YAP .
|
-
-
- HY-111820
-
|
|
Casein Kinase
p38 MAPK
|
Cardiovascular Disease
|
|
CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .
|
-
-
- HY-108573
-
P-1075
1 Publications Verification
|
Potassium Channel
|
Cardiovascular Disease
|
|
P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
|
-
-
- HY-168438
-
|
|
EGFR
Akt
ERK
|
Cardiovascular Disease
|
|
ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .
|
-
-
- HY-143248
-
|
|
G Protein-coupled Receptor Kinase (GRK)
HDAC
|
Cardiovascular Disease
|
|
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
|
-
-
- HY-149662
-
|
|
Calcium Channel
ATP Synthase
Myosin
|
Cardiovascular Disease
|
|
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC50 of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca 2+ transients. TMDJ-035 decreases ATP content and intracellular Ca 2+ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .
|
-
-
- HY-N2440
-
-
-
- HY-P3436
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
-
- HY-141552
-
FC9402
2 Publications Verification
|
Mitochondrial Metabolism
|
Cardiovascular Disease
|
|
FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation .
|
-
-
- HY-158162
-
|
|
Sirtuin
|
Cardiovascular Disease
|
|
SIRT3 activator 1 (Compound 5v) is a SIRT3 activator. SIRT3 activator 1 selectively elevates SIRT3 expression, leading to the upregulation of SOD2 and OPA1 expression, effectively preventing mitochondrial dysfunction, mitigating oxidative stress, and preserving cardiomyocyte viability. SIRT3 activator 1 can be used for research of cardiovascular diseases .
|
-
-
- HY-177204
-
|
|
Ferroptosis
Apoptosis
Glutathione Peroxidase
|
Cardiovascular Disease
|
|
DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions .
|
-
-
- HY-145237
-
BM213
3 Publications Verification
|
Complement System
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury .
|
-
-
- HY-N1910
-
|
|
SARS-CoV
Virus Protease
Succinate Receptor 1
ERK
|
Infection
Neurological Disease
|
|
4'-O-Methylbavachalcone is an orally active prenylated flavonoid that inhibits the activity of SARS-CoV papain-like protease (PLpro), with an IC50 of 10.1 μM and a Ki of 4.6 μM. 4'-O-Methylbavachalcone inhibits poly (ADP-ribose) polymerase-mediated cell death (parthanatos), reduces cerebral infarct volume, binds to the orthosteric site of SUCNR1, blocks the interaction between succinate and SUCNR1, inhibits SUCNR1 activity, blocks the nuclear translocation of NFATc4, suppresses the activation of the ERK1/2 signaling pathway, inhibits cardiomyocyte hypertrophy and restores the expression of α-actinin. 4'-O-Methylbavachalcone can be used in studies related to ischemic stroke, SARS-CoV and cardiomyocyte hypertrophy .
|
-
-
- HY-174400
-
|
|
SGLT
SOD
Na+/H+ Exchanger (NHE)
Autophagy
|
Cardiovascular Disease
|
|
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .
|
-
-
- HY-W011082
-
|
|
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
|
NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
|
-
-
- HY-129763
-
|
|
Fluorescent Dye
|
Cardiovascular Disease
|
|
Di-4-ANEPPS is a voltage-sensitive dye that acts on voltage-gated ion channels (such as sodium channels) and inhibits sodium current, significantly reducing sodium current density, although specific values like IC50 remain unclear. It mainly binds to the voltage-sensitive regions on the cell membrane, changing its fluorescence properties to reflect membrane potential changes and thus affecting the function of ion channels to exert its activity. This substance can be used in cardiovascular research, such as the electrophysiology of cardiomyocytes, myocardial ischemia, and the effects of drugs on cardiomyocytes. It is of great value in evaluating drug cardiotoxicity and exploring the mechanisms of arrhythmias .
|
-
-
- HY-118052
-
|
|
PKD
HDAC
|
Cardiovascular Disease
|
|
BPKDi is an inhibitor of PKD. BPKDi inhibits three members of the PKD family, PKD1, PKD2, and PKD3, with IC50 values of 1 nM, 9 nM, and 1 nM, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells .
|
-
-
- HY-110084
-
BTZO-1
2 Publications Verification
|
Macrophage migration inhibitory factor (MIF)
Apoptosis
|
Cardiovascular Disease
|
|
BTZO-1, a chemical probe, binds to Macrophage migration inhibitory factor (MIF) with a Kd value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro .
|
-
-
- HY-124815
-
|
|
Reactive Oxygen Species (ROS)
|
Others
|
|
CP-312 is a potent Heme Oxygenase-1 (HO-1) inducer. CP-312 protects hiPSC-CM viability by targeting the antioxidant response network through induction of HMOX1 expression. CP-312 protects human iPSC-derived cardiomyocytes from oxidative stress .
|
-
-
- HY-103346
-
|
|
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
|
-
-
- HY-153977
-
|
|
NADPH Oxidase
|
Cardiovascular Disease
|
|
GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart .
|
-
-
- HY-N2785
-
|
|
Wnt
|
Metabolic Disease
|
|
Desmethylicaritin is a phytoestrogenic molecule, has inducible effect on directional differentiation of embryonic stem cells into cardiomyocytes. Desmethylicaritin also suppresses adipogenesis via Wnt/β-catenin signaling pathway .
|
-
-
- HY-12273G
-
|
|
Organoid
TGF-β Receptor
Microtubule/Tubulin
|
Cardiovascular Disease
Neurological Disease
|
|
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
|
-
-
- HY-108649A
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro .
|
-
-
- HY-149453
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (KD: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy .
|
-
-
- HY-P1519B
-
|
BNP (1-32), rat acetate
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes) .
|
-
-
- HY-110315
-
|
|
Apoptosis
MDM-2/p53
Epigenetic Reader Domain
|
Cardiovascular Disease
|
|
Ischemin sodium is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC50 value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .
|
-
-
- HY-122610
-
-
-
- HY-119695B
-
|
Tenivastatin calcium hydrate
|
HMG-CoA Reductase (HMGCR)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Simvastatin acid (Tenivastatin) calcium hydrate is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid calcium hydrate reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid calcium hydrate can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-N8598
-
|
|
Others
|
Cardiovascular Disease
|
|
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .
|
-
-
- HY-33015A
-
|
trans-p-Chlorocinnamaldehyde
|
Enterovirus
|
Infection
|
|
4-Chlorocinnamaldehyde (trans-p-Chlorocinnamaldehyde) is an antiviral agent. 4-Chlorocinnamaldehyde inhibits the replication of Coxsackievirus B3 in cardiomyocytes, but shows poor efficacy in animal experiments. 4-Chlorocinnamaldehyde can be used in studies related to viral myocarditis .
|
-
- HY-145816
-
|
|
PROTACs
HDAC
Apoptosis
PINK1/Parkin
Autophagy
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
JPS016 is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of HDAC1, HDAC2 and HDAC3. JPS016 reduces the viability of colon cancer cells and induces Apoptosis. JPS016 activates the PINK1/Parkin mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 is applicable to research related to colon cancer and sepsis cardiomyopathy .
|
-
- HY-N0252A
-
|
(+)-3,4-Didehydrocoronaridine Tartrate
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Catharanthine ((+)-3,4-Didehydrocoronaridine) Tartrate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca 2+ channel (VOCC). Catharanthine Tartrate has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Tartrate lowers blood pressure (BP), heart rate (HR). Catharanthine Tartrate has anti-cancer activity .
|
-
- HY-P1519
-
|
BNP (1-32), rat
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Brain Natriuretic Peptide (1-32), rat (BNP (1-32), rat) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes) .
|
-
- HY-172687
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .
|
-
- HY-178345
-
|
ZZ7
|
Molecular Glues
Epigenetic Reader Domain
|
Cancer
|
|
ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer .
|
-
- HY-160706
-
|
|
Drug Derivative
|
Cardiovascular Disease
|
|
HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling .
|
-
- HY-170867
-
|
|
Keap1-Nrf2
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
Nrf2/HO-1 activator 3 (Compound C3a) is the activator for Nrf2 signaling pathway that promotes the Nrf2 translocation into nuclei and upregulates the expression of heme oxygenase-1 HO-1. Nrf2/HO-1 activator 3 inhibits the overespression of ROS and MDA in H2O2- or glucose-stimulated H9c2 cardiomyocytes, inhibits the cell viability and colony formation, thereby exhibiting antioxidant efficacy .
|
-
- HY-110315A
-
|
|
Epigenetic Reader Domain
Apoptosis
MDM-2/p53
|
Cardiovascular Disease
|
|
Ischemin is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin inhibits p53-induced p21 activation with an IC50 value of 5 µM. Ischemin also prevents apoptosis in ischemic cardiomyocytes. Ischemin can be used in the study of cardiovascular diseases (such as myocardial ischemia) .
|
-
- HY-P0084A
-
|
SRIF-14 acetate; Somatostatin-14 acetate
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Cyclic somatostatin (SRIF-14) acetate is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin acetate is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin acetate inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin acetate can be used for the research of cardiovascular disease .
|
-
- HY-118590A
-
|
|
Topoisomerase
DNA/RNA Synthesis
Apoptosis
Fungal
|
Infection
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is a DNA Topoisomerase II inhibitor. ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia .
|
-
- HY-129410
-
|
|
Endogenous Metabolite
|
Others
|
|
ADR-925 is an active chelated iron metabolite with the ability to protect neonatal rat cardiomyocytes from doxorubicin (HY-15142A)-induced damage .
|
-
- HY-106831
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
R 56865 is a cardiomyocyte protective agent that protects against digitoxin (Ouabain)-induced myocardial calcium overload. R 56865 has a protective effect against digitoxin-induced intoxication in guinea pig papillary muscle .
|
-
- HY-N2638
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
|
-
- HY-100932A
-
|
|
Myosin
|
Cancer
|
|
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
|
-
- HY-N11449
-
|
|
Others
|
Others
|
|
Nardoaristolone B, a non-sesquiterpene compound isolated from the root of Nardostachys jatamansi, has protective effects on cardiomyocyte injury in neonatal rats .
|
-
- HY-P3436A
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
- HY-149173
-
-
- HY-119695AR
-
|
Tenivastatin ammonium (Standard)
|
Reference Standards
HMG-CoA Reductase (HMGCR)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Simvastatin acid (ammonium) (Standard) is the analytical standard of Simvastatin acid (ammonium). This product is intended for research and analytical applications. Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
- HY-119695AS1
-
-
- HY-W011616
-
|
CDNG1/vuc230
|
Wnt
|
Cardiovascular Disease
Cancer
|
|
Cardionogen 1 (CDNG1/vuc230) is a Wnt signaling pathway inhibitor that slows down Myc-induced liver tumorigenesis. Cardionogen 1 treatment of zebrafish embryos before gastrulation inhibits cardiomyocyte formation, whereas treatment during or after gastrulation induces cardiomyocyte formation. Cardionogen 1 has potential in research into cancer and cardiovascular disease .
|
-
- HY-150039
-
|
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG-271423 is a potent and selective GRK5 inhibitor with IC50 values of 0.0021 μM and 44 μM for GRK5 and GRK2, respectively. CCG-271423 inhibits cardiomyocyte contractility and decreases in Ca 2+ transience . CCG-271423 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-131041
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca 2+ oscillations in cardiomyocytes .
|
-
- HY-101016R
-
|
|
Reference Standards
Cytochrome P450
Apoptosis
|
Cardiovascular Disease
|
|
17-ODYA (Standard) is the analytical standard of 17-ODYA. This product is intended for research and analytical applications. 17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes[1][2][3]. 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N10642
-
|
|
Others
|
Others
|
|
Pedaliin 6''-acetate (compound 10) is a natural product that can be isolated from Dracocephalum tanguticum. Pedaliin 6''-acetate shows antioxidative activity and cytoprotective effect on doxorubicin (DOX)-induced toxicity in H9c2 cardiomyocytes with an EC50 value of 19.1 μM .
|
-
- HY-129670
-
-
- HY-124815R
-
|
|
Reactive Oxygen Species (ROS)
|
Others
|
|
CP-312 (Standard) is the analytical standard of CP-312. This product is intended for research and analytical applications. CP-312 is a potent Heme Oxygenase-1 (HO-1) inducer. CP-312 protects hiPSC-CM viability by targeting the antioxidant response network through induction of HMOX1 expression. CP-312 protects human iPSC-derived cardiomyocytes from oxidative stress .
|
-
- HY-W402074
-
|
Butenolide
|
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
5-Acetamide-Butenolide (Butenolide) is a mycotoxin with pro-oxidant activity, which is found in Fusarium. 5-Acetamide-Butenolide disrupts the mitochondrial membrane potential in primary neonatal rat cardiomyocytes. 5-Acetamide-Butenolide also induces the production of thiobarbituric acid reactive substances (TBARS) in isolated rat myocardial mitochondria. 5-Acetamide-Butenolide increases the production of reactive oxygen species (ROS), decreases the levels of GSH and reduces the viability of HepG2 cells .
|
-
- HY-N0252B
-
|
(+)-3,4-Didehydrocoronaridine Sulfate
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Catharanthine ((+)-3,4-Didehydrocoronaridine) Sulfate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca 2+ channel (VOCC). Catharanthine Sulfate has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Sulfate lowers blood pressure (BP), heart rate (HR). Catharanthine Sulfate has anti-cancer activity .
|
-
- HY-N0252R
-
|
(+)-3,4-Didehydrocoronaridine (Standard)
|
Reference Standards
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Catharanthine (Standard) is the analytical standard of Catharanthine. This product is intended for research and analytical applications. Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca2+ channel (VOCC). Catharanthine has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity .
|
-
- HY-106749
-
-
- HY-165363
-
|
|
Drug Derivative
Lactate Dehydrogenase
ATP Synthase
|
Cardiovascular Disease
|
|
AK-135 hydrochloride is a Menadione (HY-B0332) derivative. AK-135 hydrochloride restores the electron flow in defective respiratory chain systems. AK-135 hydrochloride decreases LDH release, increases the amount of ATP. AK-135 hydrochloride has a protective effect against myocardial injury .
|
-
- HY-130272
-
|
|
Drug Derivative
|
Cardiovascular Disease
|
|
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
|
-
- HY-119695S
-
|
Tenivastatin-d6
|
Isotope-Labeled Compounds
HMG-CoA Reductase (HMGCR)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
Simvastatin acid-d6 (Tenivastatin-d6) is deuterium labeled Simvastatin acid. Simvastatin acid (Tenivastatin), a hydrolysate of Simvastatin (HY-17502), is a HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
- HY-P3868A
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis .
|
-
- HY-119850A
-
|
ARM036 sodium; S44121 sodium
|
Calcium Channel
|
Cardiovascular Disease
|
|
Aladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca 2+ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .
|
-
- HY-173005
-
|
|
PI3K
Akt
GSK-3
Apoptosis
|
Cardiovascular Disease
|
|
JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models .
|
-
- HY-P10773
-
-
- HY-108573R
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
P-1075 (Standard) is the analytical standard of P-1075. This product is intended for research and analytical applications. P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
|
-
- HY-149736
-
|
|
PKA
ATP Synthase
|
Cardiovascular Disease
|
|
ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis .
|
-
- HY-19117
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
BRL-32872 is a potent human ether-a-go-go-related gene (hERG) potassium channel blocker (IC50=241 nM in isolated cardiomyocytes; 19.8 nM in HEK293 cells). BRL-32872 is promising for research of cardiac arrhythmias (e.g., atrial/ventricular rhythms) .
|
-
- HY-183567
-
|
|
Ferroptosis
Glutathione Peroxidase
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
Ferroptosis-IN-27 is a glutathione peroxidase (GPx) mimetic. Ferroptosis-IN-27 inhibits oxidative stress, reduces intracellular ROS levels, decreases lipid peroxidation and alleviates ferrous ion overload, thereby inhibiting ferroptosis and protecting cardiomyocytes from Doxorubicin (HY-15142A)-induced injury. Ferroptosis-IN-27 can be used in studies related to Doxorubicin-induced cardiotoxicity .
|
-
- HY-103346R
-
|
|
Reference Standards
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
MMPSI (Standard) is the analytical standard of MMPSI (HY-103346). This product is intended for research and analytical applications. MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
|
-
- HY-W207224
-
|
|
MAP4K
|
Cardiovascular Disease
Inflammation/Immunology
|
|
F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
|
-
- HY-177204A
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG1000-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG1000-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-177204B
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG3400-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG3400-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-177204C
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG5000-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG5000-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-133240
-
|
|
DNA Alkylator/Crosslinker
Calcium Channel
Potassium Channel
Sodium Channel
|
Infection
|
|
trans-AzoTAB is a photoresponsive potassium/sodium/calcium channel modulator and DNA-binding agent. trans-AzoTAB undergoes trans-cis isomerization driven by light, with variable polarity and DNA affinity. trans-AzoTAB also enhances voltage-gated potassium currents and inhibits sodium and calcium currents in cardiomyocytes, thereby reducing spontaneous electrical activity and excitation conduction velocity. In addition, trans-AzoTAB induces compaction and frozen conformation of λ-phage DNA, and non-sequence-dependently inhibits transcription and translation processes in the dark; its activity can be reversed and restored by visible light after activation with ultraviolet irradiation. trans-AzoTAB can serve as a probe for two-photon optical regulation of myocardial excitability, and is used to construct photoresponsive interfacial polymer structures .
|
-
- HY-P3436B
-
-
- HY-120718
-
|
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes . CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension .
|
-
- HY-100744R
-
|
NSC51355 (Standard)
|
Histone Demethylase
Reference Standards
|
Cardiovascular Disease
|
|
AS8351 (Standard) is the analytical standard of AS8351 (HY-100744). This product is intended for research and analytical applications. AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells .
|
-
- HY-100932
-
ML-9
5 Publications Verification
|
Myosin
|
Cancer
|
|
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
|
-
- HY-100472R
-
|
|
Caspase
Reference Standards
|
Cancer
|
|
ZYZ-488 (Standard) is the analytical standard of ZYZ-488 (HY-100472). This product is intended for research and analytical applications. ZYZ-488 is a competitive apoptotic protease activating factor-1 (Apaf-1) inhibitor. ZYZ-488 inhibits the activation of binding protein procaspase-9 and procaspase-3 .
|
-
- HY-100472
-
|
|
Caspase
|
Cancer
|
|
ZYZ-488 is a competitive apoptotic protease activating factor-1 (Apaf-1) inhibitor. ZYZ-488 inhibits the activation of binding protein procaspase-9 and procaspase-3 .
|
-
- HY-101017
-
-
- HY-100932R
-
|
|
Myosin
Reference Standards
|
Cancer
|
|
ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
|
-
- HY-W015061R
-
-
- HY-174706
-
|
|
mRNA
|
Cardiovascular Disease
|
|
Human FGF16 mRNA encodes the human fibroblast growth factor 16 (FGF16) protein, a member of the fibroblast growth factor (FGF) family. FGF16 probably plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. It is also required for normal cardiomyocyte proliferation and heart development.
|
-
- HY-168130
-
|
|
TNF Receptor
Interleukin Related
|
Cardiovascular Disease
|
|
TNF-α/IL-1β-IN-1 (compund 11a) is an anti-inflammatory agent that reduces the expression of TNF-α and IL-1β, inhibits oxidative stress and cardiomyocyte apoptosis, has good activity against septic myocardial injury, and improves myocardial blood supply in vivo .
|
-
- HY-137063
-
|
|
TGF-beta/Smad
TGF-β Receptor
|
Cardiovascular Disease
|
|
(+)-ITD-1 is an inhibitor for TGF-β, that inhibits the TGF-β2 with an IC50 of 0.46 μM. (+)-ITD-1 promotes the degradation of TGF-b type II receptor (TGFBR2) and the differentiation of cardiomyocyte, and inhibits the mesoderm formation in the early differentiation stage of mouse embryonic stem cells (mESCs) .
|
-
- HY-120168
-
|
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG 258001 is a GRK inhibitor with IC50 values of 0.29, 51.8, and 33 µM against GRK2, GRK1, and GRK5, respectively. CCG 258001 inhibits GRK activity in cardiomyocytes and other muscle cells. CCG 258001 is applicable to the research of heart diseases, including heart failure, myocardial hypertrophy, and hypertension .
|
-
- HY-101415
-
|
Ubiquinone Q9; CoQ9; Ubiquinone 9
|
Apoptosis
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .
|
-
- HY-14924
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .
|
-
- HY-146441
-
|
|
STAT
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Prohibitin ligand 1 (Compound 22i), a cardioprotectant prohibitin ligand, induces a phosphorylation of the pro-survival factor STAT3. Prohibitin ligand 1 exhibits in vitro cardioprotectant activities at nanomolar concentrations .
|
-
- HY-119678
-
|
|
AMPK
Keap1-Nrf2
|
Cardiovascular Disease
Metabolic Disease
|
|
Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing AMPK/Nrf2 pathway. Fortunellin can be used for diabetic cardiomyopathy research .
|
-
- HY-135746
-
-
- HY-W011082R
-
|
|
Reference Standards
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
|
NLRP3-IN-2 (Standard) is the analytical standard of NLRP3-IN-2. This product is intended for research and analytical applications. NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
|
-
- HY-N2638R
-
|
|
Reference Standards
Apoptosis
|
Cardiovascular Disease
|
|
Ilexsaponin A (Standard) is the analytical standard of Ilexsaponin A. This product is intended for research and analytical applications. Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
|
-
- HY-19089
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
DPN-205-734 is an orally administered cGMP-PDE inhibitor. DPN-205-734 exhibits positive inotropic effects in various animal cardiomyocytes. DPN-205-734 reduces blood pressure and total peripheral resistance in multiple animal models, demonstrating a debulking effect. DPN-205-734 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure .
|
-
- HY-P4911
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .
|
-
- HY-12319
-
|
|
β-catenin
Wnt
|
Cancer
|
|
Cardiogenol C is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC50=100 nM) . Cardiogenol C also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .
|
-
- HY-12319A
-
|
|
β-catenin
Wnt
|
Cardiovascular Disease
|
|
Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC50=100 nM) . Cardiogenol C hydrochloride also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C hydrochloride is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .
|
-
- HY-P11313
-
|
Rat chromogranin A367–387
|
nAChR
Akt
|
Cardiovascular Disease
|
|
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na + uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .
|
-
- HY-D3376
-
|
6-Carboxy-2',7'-dichlorodihydrofluorescein
|
Fluorescent Dye
Reactive Oxygen Species (ROS)
|
Others
|
|
6-Carboxy-H2DCFDA (6-Carboxy-2',7'-dichlorodihydrofluorescein) is a non-fluorescent, cell-permeable intracellular ROS indicator. 6-Carboxy-H2DCFDA undergoes oxidation to highly fluorescent carboxy-dichlorofluorescein (Ex/Em = 488/520 nm) .
|
-
- HY-116442
-
|
|
Xanthine Oxidase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Azapropazone is an orally active nonsteroidal anti-inflammatory agent. Azapropazone inhibits Xanthine oxidase activity with an IC50 of 70-140 μg/mL. Azapropazone exerts significant cardiomyocyte protective effects on dogs with ischemia-reperfusion injury . Azapropazone reduces arthritis. Azapropazone inhibits Adrenaline-induced platelet aggregation. Azapropazone can be used for the research of myocardial ischemia and reperfusion injury, adjuvant arthritis, and gouty arthritis .
|
-
- HY-P4911A
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .
|
-
- HY-153993
-
|
|
Endogenous Metabolite
|
Others
|
|
Pyrocatechol sulfate, a phenolic metabolite present in human plasma, is associated with the consumption of specific foods such as berries and the condition of gut microbiota. It serves as a potential urinary biomarker for kidney function, dialytic clearance, whole grain consumption, and regular coffee intake. Additionally, Pyrocatechol sulfate, along with other phenolic sulfates, plays a role in modulating various biological functions, including those related to brain health and the rhythmic beating of cardiomyocytes.
|
-
- HY-N18500
-
|
Adlumidine
|
SARS-CoV
Virus Protease
|
Cardiovascular Disease
Infection
|
|
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC50 values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.
|
-
- HY-103371R
-
|
|
Reference Standards
Chloride Channel
Potassium Channel
|
Neurological Disease
|
|
DCPIB (Standard) is the analytical standard of DCPIB (HY-103371). This product is intended for research and analytical applications. DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
|
-
- HY-103371
-
|
|
Chloride Channel
Potassium Channel
|
Neurological Disease
|
|
DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
|
-
- HY-N7491A
-
|
|
Calcium Channel
|
Cancer
|
|
ent-(+)-verticilide is a potent and selective inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels with antiarrhythmic activity. ent-(+)-verticilide inhibits RyR2-mediated diastolic Ca2+ leak and exhibits higher potency and a distinct mechanism of action compared with theDantrolene and Tetracaine. ent-(+)-verticilide is a useful tool to investigate the therapeutic potential of targeting RyR2 hyperactivity in heart and brain pathologies .
|
-
- HY-116500A
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes.
|
-
- HY-119695AS
-
|
Tenivastatin-d6 ammonium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Simvastatin acid-d6 (ammonium)mis the deuterium labeled Simvastatin acid ammonium. Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5). Simvastatin ammonium reduces indoxyl sulfate-mediated reactive oxygen species and modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
- HY-182642
-
|
|
P2X Receptor
Nucleoside Antimetabolite/Analog
|
Cardiovascular Disease
|
|
MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy .
|
-
- HY-131701
-
|
C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine; Lyso-Lactosylceramide (synthetic)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lactosyl-C18-sphingosine (C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine) is a bioactive sphingolipid that is a form of lactosylceramide but lacks the fatty acyl group. Lysolactosylceramide (1-50 μM) reduces the viability of human neutrophils in a concentration-dependent manner. Unlike lactosylceramide, Lactosyl-C18-sphingosine has no effect on protein synthesis and cell proliferation in cardiomyocytes. Lactosyl-C18-sphingosine is a lysoganglioside GM3.
|
-
- HY-N0721
-
-
- HY-N0265
-
-
- HY-101415R
-
|
Ubiquinone Q9 (Standard); CoQ9 (Standard); Ubiquinone 9 (Standard)
|
Reference Standards
Apoptosis
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Coenzyme Q9 (Standard) is the analytical standard of Coenzyme Q9. This product is intended for research and analytical applications. Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .
|
-
- HY-117181
-
|
|
Phosphodiesterase (PDE)
Adrenergic Receptor
|
Cardiovascular Disease
|
|
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
|
-
- HY-109562A
-
|
GRK2-IN-1 hydrochloride
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG258208 (GRK2-IN-1) hydrochloride is a potent and selective GRK2 (G protein-coupled receptor kinase 2) inhibitor (IC50=30 nM) while maintaining 230-fold selectivity over GRK5 (IC50=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC50=87.3 μM), PKA, and ROCK1. CCG258208 hydrochloride can be used in heart failure research .
|
-
- HY-164853
-
|
|
Pyroptosis
NOD-like Receptor (NLR)
ERK
FGFR
AMPK
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .
|
-
- HY-137986
-
|
|
Potassium Channel
|
Inflammation/Immunology
|
|
LUF7244 is a selective allosteric modulator of Kv11.1 channels. LUF7244 inhibits early afterdepolarizations. LUF7244 can be used for anti-arrhythmia research .
|
-
- HY-109562
-
|
GRKs-IN-1
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG258208 (GRK2-IN-1) is a potent and selective GRK2 (G protein-coupled receptor kinase 2) inhibitor (IC50=30 nM) while maintaining 230-fold selectivity over GRK5 (IC50=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC50=87.3 μM), PKA, and ROCK1. CCG258208 can be used in heart failure research .
|
-
- HY-P1008
-
|
Z-VD(OMe)VAD(OMe)-FMK
|
Caspase
|
Cancer
|
|
Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis .
|
-
- HY-P5904
-
|
Caveolin-1 scaffolding domain peptide
|
c-Met/HGFR
|
Others
|
|
Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) inhibits tyrosine kinases .
|
-
- HY-156863
-
-
- HY-135746S
-
-
- HY-N7032
-
|
UDP-D-Glucose disodium
|
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
-
- HY-116442R
-
|
|
Reference Standards
Xanthine Oxidase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Azapropazone (Standard) is the analytical standard of Azapropazone (HY-116442). This product is intended for research and analytical applications. Azapropazone is an orally active nonsteroidal anti-inflammatory agent. Azapropazone inhibits Xanthine oxidase activity with an IC50 of 70-140 μg/mL. Azapropazone exerts significant cardiomyocyte protective effects on dogs with ischemia-reperfusion injury . Azapropazone reduces arthritis. Azapropazone inhibits Adrenaline-induced platelet aggregation. Azapropazone can be used for the research of myocardial ischemia and reperfusion injury, adjuvant arthritis, and gouty arthritis .
|
-
- HY-113044
-
|
UDP-D-Glucose
|
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
|
-
- HY-150042
-
-
- HY-117727
-
|
MIN-102; Hydroxypioglitazone
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
- HY-B0374
-
|
BDF5895
|
Imidazoline Receptor
Adrenergic Receptor
LDLR
|
Cardiovascular Disease
Neurological Disease
|
|
Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .
|
-
- HY-N1570
-
-
- HY-153999
-
|
BT200
|
Integrin
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
|
-
- HY-111754
-
|
|
MAP4K
|
Cardiovascular Disease
|
|
DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice .
|
-
- HY-120257
-
|
|
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation .
|
-
- HY-N0265R
-
|
Akebia saponin D (Standard)
|
Reference Standards
Caspase
Apoptosis
PERK
Akt
p38 MAPK
HIF/HIF Prolyl-Hydroxylase
PPAR
|
Cardiovascular Disease
Neurological Disease
|
|
Asperosaponin VI (Standard) is the analytical standard of Asperosaponin VI. This product is intended for research and analytical applications. Asperosaponin VI is a saponin component from Dipsacus asper. Asperosaponin VI induces osteoblast differentiation through the BMP-2/p38 and ERK1/2 signaling pathways. Asperosaponin VI protects against hypoxia-induced cardiomyocyte apoptosis by activating the PI3K/Akt and CREB pathways. Additionally, Asperosaponin VI also has antidepressant and wound-healing-promoting activities .
|
-
- HY-108998
-
|
|
Histone Methyltransferase
|
Cardiovascular Disease
|
|
Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts .
|
-
- HY-N0721R
-
-
- HY-168894
-
|
|
Ferroptosis
JAK
STAT
p38 MAPK
AMPK
GSK-3
Apoptosis
HSP
TNF Receptor
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .
|
-
- HY-19230
-
|
|
Calmodulin
NO Synthase
CaMK
Calcineurin
Proteasome
Caspase
|
Cardiovascular Disease
|
|
DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against nNOS, CaM kinase II, and calcineurin (Ki: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases .
|
-
- HY-121726
-
|
|
mTOR
Autophagy
|
Cardiovascular Disease
|
|
3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model .
|
-
- HY-120960
-
|
ARA-S
|
Akt
p38 MAPK
Apoptosis
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
N-Arachidonoyl-L-serine (ARA-S) is an endocannabinoid. N-Arachidonoyl-L-serine induces phosphorylation of Akt and MAPK in endothelial cells. N-Arachidonoyl-L-serine also induces endothelium-dependent vasodilation in isolated rat mesenteric and abdominal aortas. N-Arachidonoyl-L-serine exhibits neuroprotective effects after traumatic brain injury by reducing apoptosis. N-Arachidonoyl-L-serine promotes the opening of KV7.1/KCNE1 channels in mammalian cells and shortens the action potential duration in cardiomyocytes. N-Arachidonoyl-L-serine may be used in research on cardiovascular and cerebrovascular diseases and neurological disorders .
|
-
- HY-108586R
-
|
|
Reference Standards
Potassium Channel
|
Neurological Disease
|
|
NS3623 (Standard) is the analytical standard of NS3623 (HY-108586). This product is intended for research and analytical applications. NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .
|
-
- HY-108586
-
|
|
Potassium Channel
|
Neurological Disease
|
|
NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .
|
-
- HY-145816A
-
|
|
HDAC
PROTACs
Apoptosis
PINK1/Parkin
Autophagy
Reactive Oxygen Species (ROS)
|
Cancer
|
|
JPS016 TFA is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 TFA recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of HDAC1, HDAC2 and HDAC3. JPS016 TFA reduces the viability of colon cancer cells and induces Apoptosis. JPS016 TFA activates the PINK1/Parkin mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 TFA is applicable to research related to colon cancer and sepsis cardiomyopathy .
|
-
- HY-180575
-
|
|
Nucleoside Antimetabolite/Analog
Apoptosis
AMPK
Acetyl-CoA Carboxylase
|
Cardiovascular Disease
|
|
LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin (HY-15142A)-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib (HY-15463)-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure .
|
-
- HY-N1570R
-
|
|
Reference Standards
Salt-inducible Kinase (SIK)
KLF
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
|
-
- HY-169052
-
|
|
JNK
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .
|
-
- HY-113044R
-
|
UDP-D-Glucose (Standard)
|
Reference Standards
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Uridine 5′-diphosphoglucose (Standard) (UDP-D-Glucose (Standard)) is the analytical standard of Uridine 5′-diphosphoglucose (HY-113044). This product is intended for research and analytical applications. Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
-
- HY-129115
-
|
|
Reactive Oxygen Species (ROS)
Caspase
|
Others
|
|
S1QEL1.1 is a small molecule inhibitor that specifically inhibits the generation of superoxide and hydrogen peroxide at the IQ site during reverse electron transfer in mitochondrial respiratory chain complex I (Complex I), with an IC50 of 0.07 μM. S1QEL1.1 can significantly reduce the activation of cysteine-aspartic protease (caspase) triggered by endoplasmic reticulum stress. S1QEL1.1 helps to decrease excessive proliferation of stem cells by inhibiting the Reactive Oxygen Species signaling pathway initiated by endoplasmic reticulum stress .
|
-
- HY-D0261
-
-
- HY-P10728
-
|
|
RXFP Receptor
ERK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
|
-
- HY-N3431
-
|
|
AMPK
PD-1/PD-L1
FXR
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .
|
-
- HY-P2141
-
|
TRV027
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-N7032S
-
|
UDP-D-Glucose-13C disodium
|
Isotope-Labeled Compounds
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Uridine 5′-diphosphoglucose- 13C (UDP-D-Glucose- 13C) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
|
-
- HY-N7032S1
-
|
UDP-D-Glucose-13C6 disodium
|
Isotope-Labeled Compounds
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Uridine 5′-diphosphoglucose- 13C6 (UDP-D-Glucose- 13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
|
-
- HY-175640
-
|
|
Pyroptosis
Reactive Oxygen Species (ROS)
Interleukin Related
Caspase
|
Cardiovascular Disease
|
|
Troponin-IN-1 is a troponin inhibitor. Troponin-IN-1 protects OGD/R-injured H9c2 cardiomyocytes by reducing LDH leakage, pyroptosis and ROS accumulation. Troponin-IN-1 inhibits NO production and IL-1β/TNF-α/IL-18 release in LPS (HY-D1056)-induced RAW264.7 cells. Troponin-IN-1 acts via caspase-1/GSDMD/IL-18 pathway. Troponin-IN-1 reduces myocardial infarct size in LAD-induced myocardial ischemia/reperfusion (MI/R) male rats. Troponin-IN-1 can be used for the study of myocardial ischemia/reperfusion (MI/R) injury .
|
-
- HY-P2141A
-
|
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .
|
-
- HY-Y1322
-
|
|
Environmental Pollutants
Mitophagy
Apoptosis
NF-κB
p38 MAPK
ERK
JNK
PI3K
Akt
Monoamine Oxidase
Reactive Oxygen Species (ROS)
PPAR
Indoleamine 2,3-Dioxygenase (IDO)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Triphenyl phosphate is an orally active, blood-brain barrier-permeable aryl organophosphate flame retardant and endocrine disruptor. Triphenyl phosphate disrupts mitochondrial dynamic balance through oxidative stress, induces excessive mitophagy and apoptosis, and ultimately leads to myocardial fibrosis. In the brain, Triphenyl phosphate activates the NF-κB inflammatory pathway by disrupting the gut microbiota, alters tryptophan metabolism and elevates neurotoxins, thereby inducing anxiety- and depression-like behaviors. In the skeletal and reproductive systems, Triphenyl phosphate inhibits osteoblast differentiation and induces germ cell apoptosis by suppressing the MAPK/ERK pathway and activating the JNK signal, respectively. In adipose and placental tissues, Triphenyl phosphate promotes lipid accumulation by activating the PI3K/AKT-PPARγ axis, and disrupts placental metabolism via the MAOA/ROS/NF-κB cascade, impairing neurodevelopment of offspring .
|
-
- HY-125807
-
|
|
G Protein-coupled Receptor Kinase (GRK)
Apoptosis
Reactive Oxygen Species (ROS)
Akt
p38 MAPK
|
Cardiovascular Disease
Cancer
|
|
IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin (HY-15142A) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research .
|
-
- HY-13660
-
|
KRP-203
|
LPL Receptor
Reactive Oxygen Species (ROS)
Akt
GSK-3
JAK
STAT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
|
-
- HY-109038
-
|
KRP-203 free base
|
LPL Receptor
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
Akt
GSK-3
JAK
STAT
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
|
-
- HY-122949
-
-
- HY-108594
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
PD-118057 is a hERG channel activator without causing hERG blockade. PD-118057 activates hERG channel to suppress changes in membrane excitability .
|
-
- HY-108594R
-
|
|
Reference Standards
Potassium Channel
|
Metabolic Disease
|
|
PD-118057 (Standard) is the analytical standard of PD-118057 (HY-108594). This product is intended for research and analytical applications. PD-118057 is a hERG channel activator without causing hERG blockade. PD-118057 activates hERG channel to suppress changes in membrane excitability .
|
-
- HY-122620
-
|
Hetrombopag (tautomerism); SHR-8735 (tautomerism)
|
Thrombopoietin Receptor
STAT
PI3K
ERK
Apoptosis
CDK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
|
-
- HY-145589
-
|
Hetrombopag; SHR-8735
|
Thrombopoietin Receptor
STAT
PI3K
ERK
Apoptosis
CDK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
|
-
- HY-12879G
-
|
|
Wnt
Casein Kinase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
|
-
- HY-175984
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .
|
-
- HY-P5142A
-
|
ω-ACTX-Hv1 TFA; ω-Atracotoxin-HV1 TFA
|
Insecticide
Apoptosis
Calcium Channel
Necroptosis
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
|
-
- HY-P5142
-
|
ω-ACTX-Hv1; ω-Atracotoxin-HV1
|
Insecticide
Calcium Channel
Apoptosis
Necroptosis
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
|
-
- HY-W017113
-
|
|
Environmental Pollutants
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
|
-
- HY-125339
-
|
|
COMT
Apoptosis
|
Neurological Disease
Cancer
|
|
Ro 41-0960 is a CNS-penetrant, orally active catechol-O-methyl transferase (COMT) inhibitor. Ro 41-0960 reduces dopamine catabolism, increases striatal dopamine and DOPAC levels, decreases striatal HVA levels, induces apoptosis, inhibits proliferation and extracellular matrix formation in uterine fibroid cells. Ro 41-0960 arrests or shrinks uterine fibroid lesions in rats. Ro 41-0960 can be used for the research of Parkinson’s disease, uterine leiomyomas, and breast cancer .
|
-
- HY-148826
-
|
ARC 183; BC 007
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension .
|
-
- HY-48813
-
|
|
Endogenous Metabolite
NF-κB
Interleukin Related
|
Metabolic Disease
|
|
Glycoursodeoxycholic acid 3-sulfate is a glycine-conjugated sulfated bile acid 3-sulfate, which is produced by SULT2A1-mediated sulfation of glycoursodeoxycholic acid (HY-N1424) in the liver. Glycoursodeoxycholic acid 3-sulfate attenuates the anti-inflammatory effect of glycoursodeoxycholic acid and impairs the inhibitory effect on the IL-17 and NF-κB signaling pathways. Glycoursodeoxycholic acid 3-sulfate shows a significant correlation with aortic flow velocity and BNP in patients with aortic stenosis. Glycoursodeoxycholic acid 3-sulfate is mainly used in related studies such as quantitative analysis, quality control and biochemical experiments; it often serves as a reagent for metabolomics analysis and can also be applied to research related to aortic stenosis .
|
-
- HY-W342283
-
-
- HY-W715812
-
|
|
Fungal
Apoptosis
Caspase
Reactive Oxygen Species (ROS)
MDM-2/p53
SOD
Bcl-2 Family
PERK
JNK
p38 MAPK
|
Cardiovascular Disease
Infection
Endocrinology
Cancer
|
|
Bromuconazole is a triazole fungicide with oral efficacy and blood-brain barrier permeability . Bromuconazole protects crops from various fungal contaminations. Bromuconazole exhibits cytotoxicity against a variety of cancer cells, induces G0/G1 cell cycle arrest and inhibits DNA synthesis in cancer cells, and triggers cytoskeletal structural disorder, genotoxic damage, apoptotic (apoptosis) cell death, and mitochondrial membrane depolarization. Bromuconazole activates caspase-3, induces excessive production of ROS, p53 and Bax, lipid peroxidation, increased activities of SOD and CAT, and downregulates Bcl-2. By upregulating p-ERK1/2 and p-JNK, Bromuconazole disrupts the MAPK signaling pathway, impairs the cellular stress response of human trophoblast cells and endometrial cells, and damages the implantation process . Bromuconazole is applicable to research related to glioma, colon cancer, reproductive injury (implantation dysfunction), and cardiac dysfunction .
|
-
- HY-B0298
-
|
HS-592; Meclastine
|
Histamine Receptor
mAChR
Autophagy
Apoptosis
Keap1-Nrf2
p62
mTOR
Pyroptosis
IKK
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Clemastine (HS-592; Meclastine) is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation .
|
-
- HY-183370
-
|
|
JAK
STAT
Interleukin Related
|
Inflammation/Immunology
|
|
JAK2/STAT3-IN-2 is an orally active JAK2/STAT3 inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in JAK2 and STAT3, blocks downstream signal transduction, disrupts the dimerization and nuclear translocation of STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2 inhibits the expression of IL-17A and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis .
|
-
- HY-113040A
-
|
17(R),18(S)-EETeTr
|
Calcium Channel
|
Cardiovascular Disease
|
|
(17R,18S)-Epoxyeicosatetraenoic acid (17 (R),18 (S)-EETeTr) is a physiologically active fatty acid metabolite and also a vasodilator targeting BKα. (17R,18S)-Epoxyeicosatetraenoic acid activates the outward potassium current mediated by BK channels, and this effect is independent of the BKβ1 subunit, intracellular/extracellular calcium levels, and sarcoplasmic reticulum calcium release regulated by RyR3. (17R,18S)-Epoxyeicosatetraenoic acid is produced by the epoxidation of eicosapentaenoic acid mediated by CYP1A1 variants. (17R,18S)-Epoxyeicosatetraenoic acid is applicable to research related to arrhythmia .
|
-
- HY-108659
-
|
|
P2Y Receptor
|
Inflammation/Immunology
|
|
NF340 is a P2Y11 receptor inhibitor with a pIC50 of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal cord injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular calcium 2+ concentration and cell migration in human hepatocellular carcinoma cells. NF340 is applicable to the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis and hepatocellular carcinoma .
|
-
- HY-N0712
-
|
|
Autophagy
mTOR
Akt
FXR
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .
|
-
- HY-17355B
-
|
(R)-Pramipexole; R-(+)-Pramipexole; KNS-760704
|
PINK1/Parkin
Glutathione Peroxidase
Sodium Channel
ATP Synthase
NOD-like Receptor (NLR)
Mitophagy
Ferroptosis
Autophagy
Apoptosis
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Dexpramipexole ((R)-Pramipexole) is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more .
|
-
- HY-182252
-
|
|
Na+/Ca2+ Exchanger
|
Cardiovascular Disease
|
|
SAR296968 is a Na +/Ca 2+ exchanger (NCX) subtype inhibitor with an IC50 value of 74 nM against hNCX1. SAR296968 inhibits both forward and reverse modes of NCX current. SAR296968 enhances cardiac contractility and stroke volume. SAR296968 exerts antiarrhythmic effects. SAR296968 is applicable to research related to heart failure .
|
-
- HY-15372
-
GW6471
Maximum Cited Publications
70 Publications Verification
|
PPAR
Apoptosis
|
Cancer
|
|
GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer .
|
-
- HY-W042301
-
|
|
Anion Exchangers
Carbonic Anhydrase
Endothelin Receptor
|
Cardiovascular Disease
|
|
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na +/Cl --potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl -/NaCO3 - anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca 2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .
|
-
- HY-123606
-
|
|
Protein Arginine Deiminase
MHC
|
Cardiovascular Disease
Inflammation/Immunology
|
|
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
|
-
- HY-B0384
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-100713
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-100713R
-
|
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-B0384R
-
|
|
Angiotensin-converting Enzyme (ACE)
Reference Standards
|
Cardiovascular Disease
|
|
Temocapril (hydrochloride) (Standard) is the analytical standard of Temocapril (hydrochloride). This product is intended for research and analytical applications. Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-159821
-
|
CK-4021586; CK-586
|
Myosin
|
Cardiovascular Disease
|
|
Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-129763
-
|
|
Fluorescent Dyes
|
|
Di-4-ANEPPS is a voltage-sensitive dye that acts on voltage-gated ion channels (such as sodium channels) and inhibits sodium current, significantly reducing sodium current density, although specific values like IC50 remain unclear. It mainly binds to the voltage-sensitive regions on the cell membrane, changing its fluorescence properties to reflect membrane potential changes and thus affecting the function of ion channels to exert its activity. This substance can be used in cardiovascular research, such as the electrophysiology of cardiomyocytes, myocardial ischemia, and the effects of drugs on cardiomyocytes. It is of great value in evaluating drug cardiotoxicity and exploring the mechanisms of arrhythmias .
|
-
- HY-12273G
-
|
|
Fluorescent Dyes
|
|
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
|
-
- HY-D3376
-
|
6-Carboxy-2',7'-dichlorodihydrofluorescein
|
Fluorescent Dyes
|
|
6-Carboxy-H2DCFDA (6-Carboxy-2',7'-dichlorodihydrofluorescein) is a non-fluorescent, cell-permeable intracellular ROS indicator. 6-Carboxy-H2DCFDA undergoes oxidation to highly fluorescent carboxy-dichlorofluorescein (Ex/Em = 488/520 nm) .
|
-
- HY-12879G
-
|
|
Fluorescent Dyes
|
|
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
|
| Cat. No. |
Product Name |
Type |
-
- HY-177204
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions .
|
-
- HY-12273G
-
|
|
Biochemical Assay Reagents
|
|
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
|
-
- HY-172687
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .
|
-
- HY-177204A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG1000-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-177204B
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG3400-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-177204C
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). WLSEAGPVVTVRALRGTGSW exhibits high cardiomyocyte targeting primarily through selective binding to specific receptors or molecules on the surface of cardiomyocytes. DSPE-PEG5000-WLSEAGPVVTVRALRGTGSW can be used for drug delivery .
|
-
- HY-12879G
-
|
|
Biochemical Assay Reagents
|
|
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-P1008
-
|
Z-VD(OMe)VAD(OMe)-FMK
|
Caspase
|
Cancer
|
|
Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis .
|
-
- HY-P4094
-
CTP
2 Publications Verification
Cardiac targeting peptide
|
Peptides
|
Cardiovascular Disease
|
|
CTP (cardiac targeting peptide) can transduce cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be reversibly linked (e.g. via enolases, thiol groups) to cargo (e.g. miRNAs) for delivery specifically to cardiomyocytes over all other organs .
|
-
- HY-P10728
-
|
|
RXFP Receptor
ERK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
|
-
- HY-P2141
-
|
TRV027
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P3436
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
- HY-145237
-
BM213
3 Publications Verification
|
Complement System
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury .
|
-
- HY-P5217
-
|
|
Peptides
|
Others
|
|
CSTSMLKAC (peptide 2) is a cyclic 9 amino acid sequence that mimics endogenous peptide sequences. CSTSMLKAC homes to cardiomyocytes in the ischemic myocardium .
|
-
- HY-P5904
-
|
Caveolin-1 scaffolding domain peptide
|
c-Met/HGFR
|
Others
|
|
Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) inhibits tyrosine kinases .
|
-
- HY-P1519B
-
|
BNP (1-32), rat acetate
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes) .
|
-
- HY-P4911A
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .
|
-
- HY-P5142
-
|
ω-ACTX-Hv1; ω-Atracotoxin-HV1
|
Insecticide
Calcium Channel
Apoptosis
Necroptosis
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
|
-
- HY-P4911
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .
|
-
- HY-P2141A
-
|
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P1519
-
|
BNP (1-32), rat
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Brain Natriuretic Peptide (1-32), rat (BNP (1-32), rat) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes) .
|
-
- HY-P0084A
-
|
SRIF-14 acetate; Somatostatin-14 acetate
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Cyclic somatostatin (SRIF-14) acetate is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin acetate is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin acetate inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin acetate can be used for the research of cardiovascular disease .
|
-
- HY-P11313
-
|
Rat chromogranin A367–387
|
nAChR
Akt
|
Cardiovascular Disease
|
|
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na + uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .
|
-
- HY-P3436A
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
- HY-P3868A
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis .
|
-
- HY-P10773
-
-
- HY-P3436B
-
-
- HY-P5142A
-
|
ω-ACTX-Hv1 TFA; ω-Atracotoxin-HV1 TFA
|
Insecticide
Apoptosis
Calcium Channel
Necroptosis
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
|
-
- HY-K6303
-
|
|
|
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N7032
-
|
UDP-D-Glucose disodium
|
Natural Products
Endogenous metabolite
Source Classification
|
Endogenous Metabolite
P2Y Receptor
|
|
Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
-
-
- HY-W015061
-
-
-
- HY-N0265
-
-
-
- HY-N0721
-
-
-
- HY-101415
-
-
-
- HY-W017113
-
|
|
Structural Classification
Natural Products
Classification of Application Fields
Metabolic Disease
Endogenous metabolite
Disease Research Fields
Source Classification
|
Environmental Pollutants
Endogenous Metabolite
|
|
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
|
-
-
- HY-N0252
-
-
-
- HY-N0712
-
|
|
Cardiovascular Disease
Flavonols
Structural Classification
Flavonoids
Typhaceae
Classification of Application Fields
Typha angustifolia L.
Phenols
Polyphenols
Plants
Disease Research Fields
Source Classification
|
Autophagy
mTOR
Akt
FXR
|
|
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .
|
-
-
- HY-119695A
-
-
-
- HY-N2440
-
-
-
- HY-101017
-
-
-
- HY-N1570
-
-
-
- HY-113044R
-
|
UDP-D-Glucose (Standard)
|
Natural Products
Human Gut Microbiota Metabolites
Microorganisms
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
P2Y Receptor
|
|
Uridine 5′-diphosphoglucose (Standard) (UDP-D-Glucose (Standard)) is the analytical standard of Uridine 5′-diphosphoglucose (HY-113044). This product is intended for research and analytical applications. Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
-
-
- HY-N3431
-
-
-
- HY-N1910
-
-
-
- HY-N2785
-
-
-
- HY-113044
-
-
-
- HY-W015061R
-
-
-
- HY-119678
-
|
|
Flavonoids
Flavones
Rutaceae
Citrus japonica Thunb.
Plants
Source Classification
|
AMPK
Keap1-Nrf2
|
|
Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing AMPK/Nrf2 pathway. Fortunellin can be used for diabetic cardiomyopathy research .
|
-
-
- HY-101415R
-
-
-
- HY-N0265R
-
-
-
- HY-N8598
-
-
-
- HY-N0252A
-
-
-
- HY-122949
-
-
-
- HY-N2638
-
-
-
- HY-N0721R
-
-
-
- HY-N1570R
-
-
-
- HY-N11449
-
-
-
- HY-119695AR
-
-
-
- HY-N10642
-
-
-
- HY-W402074
-
-
-
- HY-N0252B
-
-
-
- HY-N0252R
-
-
-
- HY-N2638R
-
-
-
- HY-N18500
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N7032S1
-
|
|
|
Uridine 5′-diphosphoglucose- 13C6 (UDP-D-Glucose- 13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
|
-
-
- HY-N7032S
-
|
|
|
Uridine 5′-diphosphoglucose- 13C (UDP-D-Glucose- 13C) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
|
-
-
- HY-119695AS1
-
|
|
|
Simvastatin acid-d9 ammonium is deuterated labeled Simvastatin acid ammonium (HY-119695A). Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-119695S
-
|
|
|
Simvastatin acid-d6 (Tenivastatin-d6) is deuterium labeled Simvastatin acid. Simvastatin acid (Tenivastatin), a hydrolysate of Simvastatin (HY-17502), is a HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-119695AS
-
|
|
|
Simvastatin acid-d6 (ammonium)mis the deuterium labeled Simvastatin acid ammonium. Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5). Simvastatin ammonium reduces indoxyl sulfate-mediated reactive oxygen species and modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene .
|
-
-
- HY-135746S
-
|
|
|
OR-1896-d3 is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-101016
-
17-ODYA
1 Publications Verification
|
|
Alkynes
|
|
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-150039
-
|
|
|
Alkynes
|
|
CCG-271423 is a potent and selective GRK5 inhibitor with IC50 values of 0.0021 μM and 44 μM for GRK5 and GRK2, respectively. CCG-271423 inhibits cardiomyocyte contractility and decreases in Ca 2+ transience . CCG-271423 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148826
-
|
ARC 183; BC 007
|
|
Aptamers
|
|
Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension .
|
-
- HY-153999A
-
|
BT200 sodium
|
|
Aptamers
|
|
Rondaptivon pegol (BT200) sodium is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol sodium effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol sodium inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol sodium can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
|
-
- HY-177204
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions .
|
-
- HY-153999
-
|
BT200
|
|
Aptamers
|
|
Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
|
-
- HY-172687
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .
|
-
- HY-174706
-
|
|
|
mRNA
|
|
Human FGF16 mRNA encodes the human fibroblast growth factor 16 (FGF16) protein, a member of the fibroblast growth factor (FGF) family. FGF16 probably plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. It is also required for normal cardiomyocyte proliferation and heart development.
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-12273G
-
|
|
Organoid
TGF-β Receptor
Microtubule/Tubulin
|
Cardiovascular Disease
Neurological Disease
|
|
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
|
-
-
- HY-12879G
-
|
|
Wnt
Casein Kinase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
